Products billed under this code include Doxil, Doxorubicin HCl Liposome, Doxorubicin HCl, Liposomal.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Doxil | Baxter Healthcare Corporation | 00338-0063-01 | 2 | $195.646 |
| Doxil | Baxter Healthcare Corporation | 00338-0067-01 | 5 | $489.115 |
| Doxil | Baxter Healthcare Corporation | 00338-9665-01 | 5 | $489.115 |
| Doxil | Baxter Healthcare Corporation | 00338-9667-01 | 2 | $195.646 |
| Doxorubicin HCl Liposome | Bluepoint Laboratories | 68001-0629-26 | 5 | $489.115 |
| Doxorubicin HCl Liposome | Bluepoint Laboratories | 68001-0629-36 | 2 | $195.646 |
| Doxorubicin HCl, Liposomal | Northstar RxLLC | 16714-0742-01 | 2 | $195.646 |
| Doxorubicin HCl, Liposomal | Northstar RxLLC | 16714-0856-01 | 5 | $489.115 |
| Doxorubicin HCl, Liposomal | Sagent Pharmaceuticals | 25021-0263-10 | 2 | $195.646 |
| Doxorubicin HCl, Liposomal | Sagent Pharmaceuticals | 25021-0263-25 | 5 | $489.115 |
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Doxorubicin HCl, Liposomal | Dr. Reddy's Laboratories Inc. | 43598-0283-35 | 2 | $195.646 |
| Doxorubicin HCl, Liposomal | Dr. Reddy's Laboratories Inc. | 43598-0541-25 | 5 | $489.115 |
| Doxorubicin HCl, Liposomal | Dr. Reddy's Laboratories Inc. | 43598-0682-35 | 2 | $195.646 |
| Doxorubicin HCl, Liposomal | Dr. Reddy's Laboratories Inc. | 43598-0683-25 | 5 | $489.115 |
| Doxorubicin HCl, Liposomal | Sun Pharmaceutical Global FZE. | 47335-0049-40 | 2 | $195.646 |
| Doxorubicin HCl, Liposomal | Sun Pharmaceutical Global FZE. | 47335-0050-40 | 5 | $489.115 |
| Doxorubicin HCl, Liposomal | BluePoint Laboratories | 68001-0345-26 | 5 | $489.115 |
| Doxorubicin HCl, Liposomal | BluePoint Laboratories | 68001-0345-36 | 2 | $195.646 |
| Doxorubicin HCl, Liposomal | BluePoint Laboratories | 68001-0492-36 | 2 | $195.646 |
| Doxorubicin HCl, Liposomal | BluePoint Laboratories | 68001-0493-26 | 5 | $489.115 |
| Doxorubicin HCl, Liposomal | BluePoint Laboratories | 68001-0703-36 | 2 | $195.646 |
| Doxorubicin HCl, Liposomal | BluePoint Laboratories | 68001-0704-26 | 5 | $489.115 |
| Doxorubicin HCl, Liposomal | Zydus Pharmaceuticals (USA) Inc. | 70710-1530-01 | 2 | $195.646 |
| Doxorubicin HCl, Liposomal | Zydus Pharmaceuticals (USA) Inc. | 70710-1531-01 | 5 | $489.115 |
| Doxorubicin HCl, Liposomal | Lupin Pharmaceuticals, Inc. | 70748-0339-01 | 2 | $195.646 |
| Doxorubicin HCl, Liposomal | Lupin Pharmaceuticals, Inc. | 70748-0340-01 | 5 | $489.115 |
| Doxorubicin HCl, Liposomal | Northstar RxLLC | 72603-0103-01 | 2 | $195.646 |
| Doxorubicin HCl, Liposomal | Northstar RxLLC | 72603-0200-01 | 5 | $489.115 |
| Doxorubicin HCl, Liposomal | Dr. Reddy's Laboratories Inc. | 75907-0363-01 | 2 | $195.646 |
| Doxorubicin HCl, Liposomal | Dr. Reddy's Laboratories Inc. | 75907-0364-01 | 5 | $489.115 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $97.823 | −$18.782 | 10 MG | Doxorubicin inj 10mg | v1, posted September 17, 2026 |
| 3Q26 | $116.605 | +$44.744 | 10 MG | Doxorubicin inj 10mg | v1, posted September 15, 2026 |
| 2Q26 | $71.861 | −$32.147 | 10 MG | Doxorubicin inj 10mg | v1, posted September 15, 2026 |
| 1Q26 | $104.008 | −$4.46 | 10 MG | Doxorubicin inj 10mg | v1, posted September 15, 2026 |
| 4Q25 | $108.468 | −$0.816 | 10 MG | Doxorubicin inj 10mg | v1, posted September 8, 2026 |
| 3Q25 | $109.284 | −$41.125 | 10 MG | Doxorubicin inj 10mg | v1, posted March 10, 2026 |
| 2Q25 | $150.409 | +$14.363 | 10 MG | Doxorubicin inj 10mg | v1, posted March 10, 2026 |
| 1Q25 | $136.046 | +$2.966 | 10 MG | Doxorubicin inj 10mg | v1, posted December 19, 2025 |
| 4Q24 | $133.08 | −$3.146 | 10 MG | Doxorubicin inj 10mg | v1, posted June 11, 2025 |
| 3Q24 | $136.226 | +$21.29 | 10 MG | Doxorubicin inj 10mg | v1, posted June 11, 2025 |
| 2Q24 | $114.936 | +$29.452 | 10 MG | Doxorubicin inj 10mg | v1, posted March 11, 2025 |
| 1Q24 | $85.484 | −$59.361 | 10 MG | Doxorubicin inj 10mg | v1, posted December 19, 2024 |
| 4Q23 | $144.845 | +$56.867 | 10 MG | Doxorubicin inj 10mg | v1, posted October 10, 2024 |
| 3Q23 | $87.978 | +$9.915 | 10 MG | Doxorubicin inj 10mg | v1, posted June 5, 2024 |
| 2Q23 | $78.063 | −$24.172 | 10 MG | Doxorubicin inj 10mg | v1, posted February 23, 2024 |
| 1Q23 | $102.235 | −$9.75 | 10 MG | Doxorubicin inj 10mg | v1, posted December 6, 2023 |
| 4Q22 | $111.985 | −$18.008 | 10 MG | Doxorubicin inj 10mg | v1, posted June 22, 2023 |
| 3Q22 | $129.993 | −$48.822 | 10 MG | Doxorubicin inj 10mg | v1, posted June 9, 2023 |
| 2Q22 | $178.815 | −$21.70 | 10 MG | Doxorubicin inj 10mg | v1, posted December 14, 2022 |
| 1Q22 | $200.515 | −$33.513 | 10 MG | Doxorubicin inj 10mg | v1, posted June 8, 2022 |
| 4Q21 | $234.028 | −$23.059 | 10 MG | Doxorubicin inj 10mg | v1, posted June 2, 2022 |
| 3Q21 | $257.087 | −$51.731 | 10 MG | Doxorubicin inj 10mg | v1, posted June 2, 2022 |
| 2Q21 | $308.818 | +$10.016 | 10 MG | Doxorubicin inj 10mg | v1, posted March 1, 2022 |
| 1Q21 | $298.802 | – | 10 MG | Doxorubicin inj 10mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
